SCHEMBL2166397

SCHEMBL2166397

CN1CCN(c2cc(-n3cnc(Cl)c3)nc(N)n2)CC1

nearest known ligand 0.65

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ HRH4 Q9H3N8 6/20 0.60
▸ HRH3 Q9Y5N1 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2167704 0.81 HRH4 (0.72) HRH4
SCHEMBL2167221 0.81 HRH4 (0.56) HRH4HRH3
SCHEMBL2167266 0.81 HRH4 (0.89) HRH4HRH3
SCHEMBL1024211 0.79 HRH4 (0.70) HRH4HRH3
SCHEMBL2166485 0.76 HRH4 (1.00) HRH4HRH3
SCHEMBL2166591 0.75 HRH4 (0.73) HRH4HRH3
SCHEMBL2166146 0.75 HRH4 (1.00) HRH4HRH3
SCHEMBL605178 0.75 HRH4 (0.96) HRH4HRH3
SCHEMBL607332 0.75 HRH4 (0.96) HRH4HRH3
SCHEMBL1774506 0.74 HRH4 (0.71) HRH4HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7985745-B2 Including inflammatory pain, post surgical pain, and neuropathic pain; administering a histamine H4 receptor ligand alone or in combination with a histamine H1, H2, or H3 receptor antagonist or an enzyme inhibitor ABBOTT LABORATORIES (US) 2011-07-26 — — US disclosed
US-20080194538-A1 Method for Pain Treatment ABBVIE INC. 2008-08-14 — — US disclosed
WO-2008060766-A2 HISTAMINE H4 RECEPTOR LIGANDS FOR USE IN PAIN TREATMENT ABBOTT LABORATORIES (US) 2008-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194538-A1 Method for Pain Treatment HRH4, HRH3, HRH2 HRH4 1/4885HRH3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback